Alfuzosin for Treating Acute Urinary Retention

Inclusion Criteria:

• First episode of painful AUR related to BPH requiring catheterization
• Residual volume between 500ml and 1500ml obtained at the time of catheterization and during the first one hour after catheterization

Exclusion Criteria:

• Participated in another investigational study within 3 months before recruitment
• Suspect bladder neuro-dysfunction unrelated to etiology;
• Single Bladder neck disease;
• Acute/chronic prostatitis;
• Diagnosed prostate carcinoma;
• Suspected prostate carcinoma diagnosed by ultrasound wave;
• Surgical history of prostate and urethra;
• Diagnosed/suspected abnormality in urethra structure;
• Bladder stone;
• Blood urine retention caused by any reason;
• Residual volume less than 500 ml
• Residual volume more than 1500 ml
• AUR not due to BPH
• Parkinson's disease
• Insulin dependent diabetes
• Known/suspected multiple sclerosis;
• Stroke/MI within 6 months prior to enrolment;
• AST, ALT and Creatinine > 1.5x upper limit; neutrophil < 3,000/mm³; platelet < 100,000/mm³;
• Unstable/severe heart failure;
• History of postural hypertension/hypotension;
• Known hypersensitivity to α-receptor blocker;
• Suspected/diagnosed expansible nerval disease;
• Treatment with sympathomimetic agent within 1 week prior to enrolment, except OTC drug for cold intermittently;
• Treatment with α1-receptor blocker within 1 month prior to enrolment;
• Treatment with tricyclic antidepressants, anticholinergic agents, sympathomimetic agent (other than the above reason), first generation antihistaminic, except the treatment with stable β sympathomimetic agent/ anticholinergic agents lasting more than 1 week for Asthma and COPD (Chronic Obstructive Pulmonary Disease);
• Treatment with Disopyramide

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.